
|Articles|October 1, 2003
No Quick-Fix Solution
New York - While the micronized formulation of Alloderm (Cymetra, LifeCell Corp.) is an appropriate substance for correcting certain facial defects, the physician who wants to use it may need to manage patient expectations, according to Anthony P. Sclafani, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















